Ovarian Cancer

Aspirin has a real but more modest signal in ovarian cancer.

The strongest evidence is in prevention, not treatment. The effect size is smaller than in colorectal cancer and probably smaller than in endometrial cancer. It also varies by histotype and use pattern.

Overview

Ovarian cancer is one of the most lethal gynaecological cancers because it is often diagnosed late.

That makes any credible prevention signal worth paying attention to. Aspirin has one. But the case needs honest framing. The benefit looks modest, more relevant in non-mucinous and high-grade serous disease, and still weak on post-diagnosis trial evidence. Read the pooled analysis

Key human data

Prevention and risk reduction

The key human signal comes from pooled observational data.

• Pooled analysis of 17 studies: Frequent aspirin use was associated with an overall 13% lower ovarian-cancer risk, with an odds ratio of 0.87. Read the pooled analysis

• Case-control studies: The pooled odds ratio was 0.84, which is a somewhat stronger prevention signal than the cohort estimate. Read the summary

• Cohort studies: The pooled hazard ratio was about 0.90. That still points in the same direction, but with a smaller effect size. Read the summary

• Histotype-specific signal: The best signal appears in high-grade serous and other non-mucinous cancers. The mucinous subtype looks less responsive. Read the FORCE summary

• Genetic risk: In the 2023 pooled analysis, the association was not materially changed by polygenic risk score. That suggests the aspirin signal may still matter even when inherited risk is higher. Read the pooled analysis

• Low-dose aspirin, 2024: A newer analysis linked low-dose aspirin with lower ovarian-cancer risk, especially in nulliparous women and women without cardiovascular disease history. Women with prior cardiovascular disease did not show the same benefit. Read the Nature record

This is meaningful. It is just not a large effect.

Post-diagnosis survival

Post-diagnosis data is sparse.

One Australian cohort linked regular low-dose aspirin use with better survival in late-stage ovarian cancer. Read the ABC summary

That result is interesting, but it is not enough to change practice. It remains a single supportive dataset rather than a replicated oncology trial signal.

Mechanistic relevance

COX-2 and inflammatory signalling

Ovarian tumours often show increased COX-2 expression. Higher inflammatory signalling can support tumour survival, immune escape, and resistance to platinum therapy. Aspirin fits this biology at least in principle. Read the gynaecological review

Platelet and TXA2 biology

Ovarian cancer also has strong platelet relevance.

This disease carries a high burden of cancer-associated thrombosis and platelet activation. That matters because platelets can shield tumour cells and support metastatic spread across the peritoneum. Read the review

Aspirin may matter here through platelet COX-1 inhibition and TXA2 suppression. For the broader mechanism, see Aspirin and Thromboxane A2 (TXA2).

Energy metabolism and hypoxia

More speculative work suggests aspirin may alter glutamine use and broader energy metabolism in hypoxic ovarian-cancer cells. This is still early-stage biology, not clinical evidence. Read the Scientific Reports paper

PIK3CA relevance

PIK3CA mutations are less common here than in endometrial cancer, but they still matter.

Reported rates are roughly 10% to 15%, with higher relevance in endometrioid ovarian tumours. Read the AACR pan-cancer analysis

That is not yet a validated aspirin biomarker in ovarian cancer. It is simply a plausible biology overlap.

Clinical positioning

Honest evidence assessment

This page should stay more restrained than the endometrial page.

The prevention signal is consistent enough to take seriously. But the effect size is still only around 10% to 15% in most summaries. There is no Phase 3 adjuvant trial. There is no biomarker-validated subgroup equivalent to PIK3CA-selected colorectal cancer. Post-diagnosis evidence is still thin. Read the review record

So the current clinical use case is mostly a prevention discussion, not an adjuvant-treatment conclusion.

Practical interpretation

The most useful questions for patients are:

1. What was the tumour histotype — high-grade serous, endometrioid, mucinous, or clear cell?

2. Is the main question prevention before diagnosis, or aspirin use after diagnosis?

3. Is there a history of BRCA-related or other inherited ovarian-cancer risk?

4. Is the patient nulliparous, or is there a history of cardiovascular disease that might change the balance?

5. Has tumour profiling shown anything relevant, such as PIK3CA alteration?

The signal here is worth knowing. It is just not strong enough to overstate.

References

• JAMA Network Open 2023 — pooled analysis of 17 studies and a 13% lower ovarian-cancer risk. Read the pooled analysis

• CancerWorld summary — cohort and case-control effect sizes from pooled ovarian-cancer data. Read the summary

• British Journal of Cancer 2024 — low-dose aspirin, nulliparity, and cardiovascular-disease subgroup findings. Read the Nature record

• FORCE XRAY summary — histotype-specific reduction in high-grade serous ovarian cancer. Read the summary

• Australian cohort coverage — low-dose aspirin and late-stage ovarian-cancer survival. Read the ABC summary

• Review of platelet activation and cancer-associated thrombosis in ovarian and other solid tumours. Read the review

• Yang et al., Nature 2025 — platelet TXA2, immune escape, and metastatic spread. Read the University of Cambridge summary

• Scientific Reports 2026 — aspirin and glutamine-energy metabolism in hypoxic ovarian-cancer cells. Read the paper

• AACR pan-cancer analysis — PIK3CA frequency context. Read the analysis

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form